1.Comparison of bioavailability and pharmacokinetics of diclofenac sodium and diclofenac potassium in normal and dehydrated rabbits
Ahmad MAHMOOD ; Iqbal MUHAMMAD ; Murtaza GHULAM
Acta Pharmaceutica Sinica 2009;44(1):80-84
Two different salts of diclofenac, diclofenac sodium and dielofenae potassium, in tablet dosage form were tested for their bioavailability and disposition kinetics in a group of eighteen rabbits in normal and experimentally induced dehydrated conditions with a wash out period of 7 days between both stages of study. Biochemical and physiological parameters were also measured in both normal and dehydrated states. Diclofenac levels in plasma were determined using a validated reversed phase HPLC method. Primary kinetic parameters i.e. AUC0-∞, Cmax, Tmax and other disposition kinetics were obtained with non-compartmental procedure. Biochemical parameters i.e. packed cell volume, plasma glucose and total lipid concentration in dehydrated rabbits increased significantly. Plasma concentration of diclofenac sodium and diclofenac potassium decreased significantly in water deprived rabbits. In comparison, diclofenac potassium in normal and dehydrated state of the same group of rabbits showed a significantly increased plasma concentration when compared with diclofenac sodium.
2.Anti-biofilm activity of the marine bacterium Pseudoalteromonas ruthenica KLPp3 against Serratia marcescens and Vibrio alginolyticus
Asmat Ahmad ; Mohd Faiq Iqbal Sulieman ; Gires Usup
Malaysian Journal of Microbiology 2016;12(1):30-34
Aims: Pseudoalteromonas ruthenica KLPp3 is the marine Gram-negative strain isolated from the surface of mud crab at
Pulau Perhentian Malaysia. In this work, the anti-biofilm activity of P. ruthenica supernatant was examined on Serratia
marcescen and Vibrio alginolyticus.
Methodology and results: The crude extract of P. ruthenica KLPp3 was obtained using ethyl acetate. The subminimum
inhibitory concentration (MIC) of the crude extract was determined using the minimum inhibitory test. The subMIC
crude extract was tested against two of the S. marcescen virulence factors, which are the swarming ability and
production of prodigiosin. The crystal violet assay was used to test the anti-biofilm activity of the sub-MIC crude extract
against S. marcescen and V. alginolyticus. The productions of prodigiosin were reduced by 72%. The swarming area
was reduced by 56.06%. It inhibits 26.9% and 48.5% of biofilm production in S. marcescens and V. alginolyticus
respectively. The crude extract was heat stable.
Conclusion, significance and impact of study: Besides combating the S. marcescens virulence factor, P. ruthenica
KLPp3 crude extract in sub-MIC reduces the formation of biofilm of S. marcescens and V. alginolyticus, which may find
applications in biofilm inhibition and prevention.
Anti-Infective Agents
3.Calcitriol-mediated Reversible Hypercalcemia in a Patient with Primary Adrenal Lymphoma
Shahnaz Ahmad Mir ; Shariq Rashid Masoodi ; Arshad Iqbal Wani ; Syed Nisar Ahmad ; Iqra Hameed
Malaysian Journal of Medical Sciences 2016;23(6):118-122
Primary adrenal lymphomas (PAL) are rare occurrences with only less than 150 cases
reported in the literature. Two-thirds of these cases were reported in the last decade due to the
advancements in imaging techniques and immunohistochemistry. The non-specific signs and
symptoms have resulted in a delayed onset of symptoms and diagnosis of these tumors. Reports
of the results of chemotherapy are not gratifying, and most patients die within one year of the
diagnosis. We report a 65-year-old male with adrenal non-Hodgkin’s lymphoma (NHL), who
presented with hypercalcemia and renal failure. We reviewed all adrenal NHL cases presented
with hypercalcemia and attempted to comprehend its etiology and overall survival effect.
4.Unlocking the Neurogenic Potential of Mammalian Müller Glia.
International Journal of Stem Cells 2016;9(2):169-175
Müller glia (MG) are the primary support cells in the vertebrate retina, regulating homeostasis in one of the most metabolically active tissues. In lower vertebrates such as fish, they respond to injury by proliferating and reprogramming to regenerate retinal neurons. In mammals, MG may also react to injury by proliferating, but they fail to initiate regeneration. The barriers to regeneration could be intrinsic to mammalian MG or the function of the niche that cannot support the MG reprogramming required for lineage conversion or both. Understanding these mechanisms in light of those being discovered in fish may lead to the formulation of strategies to unlock the neurogenic potential of MG and restore regeneration in the mammalian retina.
Homeostasis
;
Mammals
;
Neurogenesis
;
Neuroglia*
;
Regeneration
;
Retina
;
Retinal Neurons
;
Vertebrates
5.Comparison of bioavailability and pharmacokinetics of diclofenac sodium and diclofenac potassium in normal and dehydrated rabbits.
Mahmood AHMAD ; Muhammad IQBAL ; Ghulam MURTAZA
Acta Pharmaceutica Sinica 2009;44(1):80-84
Two different salts of diclofenac, diclofenac sodium and diclofenac potassium, in tablet dosage form were tested for their bioavailability and disposition kinetics in a group of eighteen rabbits in normal and experimentally induced dehydrated conditions with a wash out period of 7 days between both stages of study. Biochemical and physiological parameters were also measured in both normal and dehydrated states. Diclofenac levels in plasma were determined using a validated reversed phase HPLC method. Primary kinetic parameters i.e. AUC(0-infinity), Cmax, Tmax and other disposition kinetics were obtained with non-compartmental procedure. Biochemical parameters i.e. packed cell volume, plasma glucose and total lipid concentration in dehydrated rabbits increased significantly. Plasma concentration of diclofenac sodium and diclofenac potassium decreased significantly in water deprived rabbits. In comparison, diclofenac potassium in normal and dehydrated state of the same group of rabbits showed a significantly increased plasma concentration when compared with diclofenac sodium.
Administration, Oral
;
Animals
;
Anti-Inflammatory Agents, Non-Steroidal
;
administration & dosage
;
blood
;
pharmacokinetics
;
Area Under Curve
;
Biological Availability
;
Dehydration
;
metabolism
;
Diclofenac
;
administration & dosage
;
analogs & derivatives
;
blood
;
pharmacokinetics
;
Rabbits
;
Tablets
6.Allgrove (Triple A) Syndrome: A Case Report from the Kashmir Valley.
Raiz Ahmad MISGAR ; Nazir Ahmad PALA ; Mahroosa RAMZAN ; Arshad Iqbal WANI ; Mir Iftikhar BASHIR ; Bashir Ahmad LAWAY
Endocrinology and Metabolism 2015;30(4):604-606
Allgrove (Triple A) syndrome is a rare autosomal recessive disorder characterized by cardinal features of adrenal insufficiency due to adrenocorticotropic hormone (ACTH) resistance, achalasia, and alacrimia. It is frequently associated with neurological manifestations like polyneuropathy. Since its first description by Allgrove in 1978, approximately 100 cases have been reported in the literature. Here we report an 18-year-old boy diagnosed as having Allgrove syndrome, with ACTH resistant adrenal insufficiency, achalasia, alacrimia, and severe motor polyneuropathy. Alacrimia was the earliest feature evident at the age of 8 years. He presented with achalasia and adrenal insufficiency at 12 and 18 years respectively and developed neurological symptoms in the form of severe muscle wasting at the age of 15 years. Patients with Allgrove syndrome usually manifest adrenal insufficiency and achalasia during first decade of life. Our patient manifested adrenal insufficiency and achalasia in the second decade and manifested neurological dysfunction before adrenal dysfunction.
Adolescent
;
Adrenal Insufficiency
;
Adrenocorticotropic Hormone
;
Esophageal Achalasia
;
Humans
;
Male
;
Neurologic Manifestations
;
Polyneuropathies
7.Efficacy of Amitriptyline in Irritable Bowel Syndrome:A Systematic Review and Meta-analysis
Minahil IQBAL ; Sara HIRA ; Humza SAEED ; Sufyan SHAHID ; Suha T BUTT ; Kamran RASHID ; Mohammad AHMAD ; Hammad HUSSAIN ; Anzalna MUGHAL ; Gabriel P A COSTA ; Fernanda GUSHKEN ; Neil NERO ; Shreya SENGUPTA ; Akhil ANAND
Journal of Neurogastroenterology and Motility 2025;31(1):28-37
Background/Aims:
Amitriptyline is prescribed off-label for irritable bowel syndrome (IBS). We conducted a meta-analysis to assess its efficacy.
Methods:
A systematic literature review was conducted until November 10, 2023, using MEDLINE, Embase, Cochrane Library, and Web of Science to study the efficacy of amitriptyline in patients with IBS. We included all randomized controlled trials that compared amitriptyline to placebo. Revised Cochrane risk-of-bias tool was used to assess the quality of studies. Meta-analyses were performed using a bivariate random-effects model. Statistical analyses were performed using R Software 4.2.3 and heterogeneity was assessed with I 2 statistics.
Results:
Seven trials were included with 796 patients (61% female). Amitriptyline was associated with better treatment response (OR, 5.30; 95% CI, 2.47 to 11.39; P < 0.001), reduced Irritable Bowel Syndrome Symptom Severity Scores (MD, –50.72; 95% CI, –94.23 to –7.20; P = 0.020) and improved diarrhea (OR, 10.55; 95% CI, 2.90 to 38.41; P < 0.001). No significant difference between the 2 groups regarding the adverse effects was observed. Three trials showed an overall low risk of bias, 2 trials showed an overall high risk of bias due to randomization and missing data, and 2 trials had some concerns regarding missing data.
Conclusions
Amitriptyline was found to be well-tolerated and effective in treating IBS compared to placebo. These findings support the use of amitriptyline for the management of IBS, particularly among patients with the IBS diarrhea subtype. Future research should focus on the dose-dependent effects of amitriptyline in IBS to better guide clinicians in personalized titration regimens.
8.Efficacy of Amitriptyline in Irritable Bowel Syndrome:A Systematic Review and Meta-analysis
Minahil IQBAL ; Sara HIRA ; Humza SAEED ; Sufyan SHAHID ; Suha T BUTT ; Kamran RASHID ; Mohammad AHMAD ; Hammad HUSSAIN ; Anzalna MUGHAL ; Gabriel P A COSTA ; Fernanda GUSHKEN ; Neil NERO ; Shreya SENGUPTA ; Akhil ANAND
Journal of Neurogastroenterology and Motility 2025;31(1):28-37
Background/Aims:
Amitriptyline is prescribed off-label for irritable bowel syndrome (IBS). We conducted a meta-analysis to assess its efficacy.
Methods:
A systematic literature review was conducted until November 10, 2023, using MEDLINE, Embase, Cochrane Library, and Web of Science to study the efficacy of amitriptyline in patients with IBS. We included all randomized controlled trials that compared amitriptyline to placebo. Revised Cochrane risk-of-bias tool was used to assess the quality of studies. Meta-analyses were performed using a bivariate random-effects model. Statistical analyses were performed using R Software 4.2.3 and heterogeneity was assessed with I 2 statistics.
Results:
Seven trials were included with 796 patients (61% female). Amitriptyline was associated with better treatment response (OR, 5.30; 95% CI, 2.47 to 11.39; P < 0.001), reduced Irritable Bowel Syndrome Symptom Severity Scores (MD, –50.72; 95% CI, –94.23 to –7.20; P = 0.020) and improved diarrhea (OR, 10.55; 95% CI, 2.90 to 38.41; P < 0.001). No significant difference between the 2 groups regarding the adverse effects was observed. Three trials showed an overall low risk of bias, 2 trials showed an overall high risk of bias due to randomization and missing data, and 2 trials had some concerns regarding missing data.
Conclusions
Amitriptyline was found to be well-tolerated and effective in treating IBS compared to placebo. These findings support the use of amitriptyline for the management of IBS, particularly among patients with the IBS diarrhea subtype. Future research should focus on the dose-dependent effects of amitriptyline in IBS to better guide clinicians in personalized titration regimens.
9.Efficacy of Amitriptyline in Irritable Bowel Syndrome:A Systematic Review and Meta-analysis
Minahil IQBAL ; Sara HIRA ; Humza SAEED ; Sufyan SHAHID ; Suha T BUTT ; Kamran RASHID ; Mohammad AHMAD ; Hammad HUSSAIN ; Anzalna MUGHAL ; Gabriel P A COSTA ; Fernanda GUSHKEN ; Neil NERO ; Shreya SENGUPTA ; Akhil ANAND
Journal of Neurogastroenterology and Motility 2025;31(1):28-37
Background/Aims:
Amitriptyline is prescribed off-label for irritable bowel syndrome (IBS). We conducted a meta-analysis to assess its efficacy.
Methods:
A systematic literature review was conducted until November 10, 2023, using MEDLINE, Embase, Cochrane Library, and Web of Science to study the efficacy of amitriptyline in patients with IBS. We included all randomized controlled trials that compared amitriptyline to placebo. Revised Cochrane risk-of-bias tool was used to assess the quality of studies. Meta-analyses were performed using a bivariate random-effects model. Statistical analyses were performed using R Software 4.2.3 and heterogeneity was assessed with I 2 statistics.
Results:
Seven trials were included with 796 patients (61% female). Amitriptyline was associated with better treatment response (OR, 5.30; 95% CI, 2.47 to 11.39; P < 0.001), reduced Irritable Bowel Syndrome Symptom Severity Scores (MD, –50.72; 95% CI, –94.23 to –7.20; P = 0.020) and improved diarrhea (OR, 10.55; 95% CI, 2.90 to 38.41; P < 0.001). No significant difference between the 2 groups regarding the adverse effects was observed. Three trials showed an overall low risk of bias, 2 trials showed an overall high risk of bias due to randomization and missing data, and 2 trials had some concerns regarding missing data.
Conclusions
Amitriptyline was found to be well-tolerated and effective in treating IBS compared to placebo. These findings support the use of amitriptyline for the management of IBS, particularly among patients with the IBS diarrhea subtype. Future research should focus on the dose-dependent effects of amitriptyline in IBS to better guide clinicians in personalized titration regimens.
10.Non-occupational lead exposure and hypertension in Pakistani adults.
Sohaila RAHMAN ; Nasir KHALID ; Jamshed Hussain ZAIDI ; Shujaat AHMAD ; Mohammad Zafar IQBAL
Journal of Zhejiang University. Science. B 2006;7(9):732-737
Hypertension is one of the most prevalent diseases in the developed and developing countries. Based on the long historical association and the provocative findings of blood pressure effects at low level of lead exposure a study was carried out to determine if an association existed between low blood lead concentration and hypertension. In this study the effects of low-level exposure to lead on blood pressure were examined among 244 adults using atomic absorption spectrometer. For quality assurance purpose certified reference materials i.e., Animal blood A-13, Bovine liver 1577 and cotton cellulose V-9 from IAEA (International Atomic Energy Agency) and NIST (National Institute of Standard Technology) were analyzed under identical experimental conditions. The mean age of hypertensive adults was 52 years (range 43 - 66). The mean values of systolic and diastolic blood pressure were (209+/-11.7) (range 170 - 250) and (117+/-3.9) (range 105 - 140) mmHg respectively. Blood lead concentration ranged from 78 - 201 microg/L with a mean of 139 microg/L and 165 - 497 microg/L with a mean of 255 microg/L in normal and hypertensive adults respectively. Increase in systolic blood pressure was significantly predictive with increase in blood lead levels. Body mass index (BMI) and lipid profile including total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol and triglyceride correlated with blood pressure.
Adult
;
Blood Pressure
;
drug effects
;
Body Mass Index
;
Cholesterol
;
blood
;
Environmental Exposure
;
Female
;
Humans
;
Hypertension
;
chemically induced
;
Lead
;
blood
;
toxicity
;
Male
;
Middle Aged
;
Occupational Exposure